Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Autoimmune Monoclonal Antibody Market Expected to Grow Between 2025 And 2029?
In recent times, the autoimmune monoclonal antibody market has been experiencing robust growth. The market size is projected to expand from $65.83 billion in 2024 to $70.86 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this growth during the historic period include a higher incidence of autoimmune diseases, increasing utilization of biologics for treatment, growing awareness about targeted therapies, early authorization of monoclonal antibody drugs, and the enlargement of healthcare systems in developed nations.
In the coming years, the autoimmune monoclonal antibody sector is set to experience robust growth. It is expected to expand to a market size of $96.74 billion by 2029, with an 8.1% compound annual growth rate (CAGR). Key contributors to this anticipated growth during the forecast period are the growing demand for personalized medicine, rising use of biosimilars, increase in autoimmune therapy clinical trials, aging human population, and a surge in chronic immune disorders’ occurrence. Some major future trends include advancements in antibody engineering, the progression of bispecific antibodies, increased utilization of AI in drug discovery, the incorporation of genomics in treatment strategies, and introduction of new drug delivery systems.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp
Which Primay Drivers Are Accelerating Growth in the Autoimmune Monoclonal Antibody Market?
The rise in demand for biological treatment is anticipated to spur the expansion of the autoimmune monoclonal antibody marketplace. Biologics, products derived from living organisms, are employed in the treatment, prevention, or diagnosis of ailments. The escalating requirement for these products is principally due to their proficiency in dealing with challenging illnesses, such as cancer, autoimmune diseases, and genetic disorders, where conventional therapies may fall short. Autoimmune monoclonal antibodies bolster biologic procedures by providing focused immune modulation. They curtail the necessity for extensive immunosuppressants by presenting accurate treatments, enhancing patient outcomes, and mitigating side effects. For example, in June 2024, Cardinal Health Inc., an American healthcare company, reported that the Food and Drug Administration (FDA) approved 40 biosimilar items in 2023, with 25 being commercially accessible in the US market, a progression from the 33 biosimilar products in 2022. Consequently, the mounting appeal for biologics is contributing to the progression of the autoimmune monoclonal antibody market.
Which Primary Segments of the Autoimmune Monoclonal Antibody Market Are Driving Growth and Industry Transformations?
The autoimmune monoclonal antibody market covered in this report is segmented –
1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions
Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp
Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Autoimmune Monoclonal Antibody Market?# Market?
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Technological Trends Are Reshaping the Autoimmune Monoclonal Antibody Industry Dynamics?
Main players in the autoimmune monoclonal antibody sector are emphasizing the development of innovative treatments, like biosimilar development, which are designed to boost safety, quality, and effectiveness. Biosimilar development involves the generation of bio-products similar to, and as safe and effective as, pre-existing approved biologics, employing sophisticated biotechnology, meticulous analytical examinations, and clinical trials to prove their safety, quality, and effectiveness for regulatory endorsement. One such example occurred on February 2025, when Biocon Biologics Limited, a bioscience firm based in India, introduced YESINTEK, a biosimilar targeting autoimmune ailments like Crohn’s disease, ulcerative colitis, and psoriasis by modulating the activities of interleukin-12 and interleukin-23, therefore reducing inflammation and managing immune responses. By emulating the referential product stelara, Yesintek aids in long-term disease control while enhancing patient accessibility to biologic treatments.
View the full report here:
What Parameters Are Used to Define the Autoimmune Monoclonal Antibody Market?
Autoimmune monoclonal antibodies are lab-made proteins designed to target specific components of the immune system involved in autoimmune diseases. These antibodies help regulate or block abnormal immune responses that mistakenly attack the body’s own tissues. Their main purpose is to reduce inflammation and prevent the immune system from attacking the body’s own tissues, thereby minimizing damage and maintaining normal physiological function.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24162
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
